Stifel lowered the firm's price target on Inventiva to $15 from $17 and keeps a Buy rating on the shares. The firm notes the company is in final stretches of its pivotal NATiV3 of lanifibranor/Lani in MASH, which reads out in Q4 2026. Expectations for this trial success are high given the strong powering, longer duration trial, and the well-screened population, Stifel adds. In parallel, Inventiva is establishing the Lani profile for its ability to address the underlying metabolic dysfunction related to liver disease - making it ideally suited for the T2D MASH population. Though the market is served by Rezdiffra and Wegovy, Stifel believes Lani can find clear positioning within this commercial offering.
